Related Experiment Videos
Enhanced antiopiate activity and enzyme resistance in peptidomimetics of FMRFamide containing
Abstract:
FMRFamide is a molluscan peptide that has shown antiopiate activity in a number of mammalian test systems. The current study determined the antiopiate potency of FMRFamide and two conformationally constrained peptidomimetics of FMRFamide containing stereoisomers of (E)-2,3-methanomethionine. Morphine abstinence signs were observed after varying doses (0.25-25.0 microgram) of these substances were injected into the third ventricle of morphine-dependent rats. Both peptidomimetics were far more potent than FMRFamide itself. In addition, although both peptidomimetics bound with lower affinity than FMRFamide to rat spinal cord receptors for NPFF (the mammalian FMRFamide-like peptide), they were far more resistant than FMRFamide to enzymatic degradation by leucine aminopeptidase.
Insights
Two novel peptidomimetics of FMRFamide demonstrated superior antiopiate potency compared to the original peptide in rat models. These compounds show promise for managing opiate withdrawal symptoms.
Area of Science:
- Neuropharmacology
- Peptide Chemistry
- Opiate Receptor Research
Background:
- FMRFamide, a molluscan peptide, exhibits antiopiate effects in mammalian systems.
- Understanding FMRFamide-like peptide (NPFF) receptor interactions is crucial for pain and addiction research.
Purpose of the Study:
- To evaluate the antiopiate potency of FMRFamide and its novel peptidomimetics.
- To compare the receptor binding affinity and enzymatic stability of these compounds.
Main Methods:
- Administration of FMRFamide and peptidomimetics into the rat third ventricle.
- Observation of morphine abstinence signs in dependent rats.
- Assessment of binding affinity to rat spinal cord NPFF receptors.
- Evaluation of resistance to leucine aminopeptidase degradation.
Main Results:
- Both peptidomimetics exhibited significantly higher antiopiate potency than FMRFamide.
- Peptidomimetics displayed lower affinity for NPFF receptors compared to FMRFamide.
- Peptidomimetics demonstrated greater resistance to enzymatic degradation than FMRFamide.
Conclusions:
- Conformationally constrained peptidomimetics of FMRFamide possess enhanced antiopiate activity.
- Increased enzymatic stability contributes to the heightened potency of these peptidomimetics.
- These findings suggest potential therapeutic applications for novel FMRFamide analogs in managing opiate dependence.